Business
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer
SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced the appointment of Alexandra Kropotova, M.D., as Chief Medical Officer (CMO), to play a critical role in progressing SAB’s proprietary immune and autoimmune disorders pipeline. Dr. Kropotova brings to SAB more than 20 years of experience in all phases of global clinical development, translational medicine and medical affairs. Prior to joining SAB, Dr. Kropotova was the Therapeutic Area Head at Global Specialty R&D at Teva Pharmaceuticals, where she led innovative drug development focused on delivering on a broad portfolio of immunology, respiratory, and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products. “Dr. Kropotova is an essential addition to our executive team at SAB,” said Samuel J. Reich, Executive Chairman of SAB Biotherapeutics. “Her impressive track record will be paramount in advancing a robust pipeline spanning immune and autoimmune disorders and ultimately, treating patients in need around the globe.” “We are excited to welcome Dr. Kropotova to the SAB team as our new Chief Medical Officer,” said Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics. “Having contributed to the filing of numerous patents and brought a number of new compounds into research and development programs, Dr. Kropotova is joining SAB at the perfect time. Her proven expertise will be instrumental as SAB builds upon our initial proof-of-concept and progresses our discovery and early stage programs in infectious disease, oncology, type 1 diabetes and organ transplantation induction/rejection.” Prior to her tenure at Teva, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D Clinical Development; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. She served in various roles at Pfizer Inc., most recently as Director & Head of Global C...